Published in Oncogene on June 03, 1999
Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol (2009) 0.97
Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. World J Gastroenterol (2003) 0.95
Comparative analysis of p73 and p53 regulation and effector functions. J Cell Biol (1999) 0.94
Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic Acids Res (2008) 0.92
Evaluation of 1p losses in primary carcinomas, local recurrences and peripheral metastases from colorectal cancer patients. Neoplasia (2001) 0.89
Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol (2012) 0.86
p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer (2001) 0.84
Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer (2001) 0.84
Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem (2014) 0.83
Alterations of p63 and p73 in human cancers. Subcell Biochem (2014) 0.81
Local mitochondrial-endolysosomal microfusion cleaves voltage-dependent anion channel 1 to promote survival in hypoxia. Mol Cell Biol (2015) 0.80
Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas. Mol Cancer (2005) 0.78
LncRNA pathway involved in premature preterm rupture of membrane (PPROM): an epigenomic approach to study the pathogenesis of reproductive disorders. PLoS One (2013) 0.78
Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. Sci Rep (2016) 0.77
Proteasome inhibitors suppress the protein expression of mutant p53. Cell Cycle (2014) 0.76
Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung adenocarcinoma cell line. Oncol Lett (2015) 0.75
The dominant-negative interplay between p53, p63 and p73: A family affair. Oncotarget (2016) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet (2001) 6.23
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (1991) 6.16
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell (1999) 5.28
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (1989) 3.80
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res (1998) 3.74
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10
Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci U S A (1986) 2.93
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
Distribution and modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol (1987) 2.87
Isotope bone imaging in suspected scaphoid trauma. Br J Radiol (1981) 2.87
Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst (1999) 2.83
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet (2001) 2.82
GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A (1999) 2.80
Detection and differentiation of picornaviruses in clinical samples following genomic amplification. J Gen Virol (1990) 2.77
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene (2007) 2.71
Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors. Cell (1989) 2.65
Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res (1996) 2.65
Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A (1994) 2.64
Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. Bull World Health Organ (1991) 2.36
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res (1999) 2.36
Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm (2001) 2.34
Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res (2000) 2.31
Analysis of heart rate variability demonstrates effects of development on vagal modulation of heart rate in healthy children. J Pediatr (1997) 2.24
Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. J Urol (1999) 2.24
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene (1999) 2.19
Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res (1997) 2.17
Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res (1998) 2.15
An audit of blood cross-match ordering practices at the Aga Khan University Hospital: first step towards a Maximum Surgical Blood Ordering Schedule. J Pak Med Assoc (2001) 2.15
HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum (1989) 2.14
Improved SPECT quantification using compensation for scattered photons. J Nucl Med (1984) 2.14
Identification of a novel GC-rich 113-nucleotide region to complete the circular, single-stranded DNA genome of TT virus, the first human circovirus. J Virol (1999) 2.13
Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene (1999) 2.12
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst (1999) 2.10
Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A (1990) 2.07
Folk use of medicinal herbs of Margalla Hills National Park, Islamabad. J Ethnopharmacol (2000) 2.04
Eye injuries in road traffic accidents. Ir Med J (1983) 2.03
DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci U S A (2001) 2.00
Impact of measles vaccination on childhood mortality in rural Bangladesh. Bull World Health Organ (1990) 1.95
End of exile for Taiwan. Lancet (2000) 1.94
Altered differentiation of mouse epidermal cells treated with retinyl acetate in vitro. Exp Cell Res (1974) 1.94
Transformation of human bronchial epithelial cells transfected by Harvey ras oncogene. Science (1985) 1.88
Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res (1991) 1.88
Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Arch Dermatol (1991) 1.88
Fever and pneumonia after flexible fiberoptic bronchoscopy. Am Rev Respir Dis (1975) 1.87
The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I. J Biol Chem (1999) 1.84
Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A (1993) 1.84
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (1993) 1.84
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res (2000) 1.81
Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med (1995) 1.75
Maternal mortality in Matlab, Bangladesh: 1976-85. Stud Fam Plann (1988) 1.73
Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. J Am Coll Cardiol (1996) 1.72
Organophosphate Poisoning in Cattle with Particular reference To Co-Ral. Can Vet J (1961) 1.72
Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum (1982) 1.71
Standard management of acute respiratory infections in a children's hospital in Pakistan: impact on antibiotic use and case fatality. Bull World Health Organ (1996) 1.70
Comparative yield of Salmonella typhi from blood and bone marrow cultures in patients with fever of unknown origin. J Clin Pathol (1991) 1.70
The SAPHO syndrome. Baillieres Clin Rheumatol (1994) 1.69
Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart (2003) 1.69
Pilot trial of IOM duty hour recommendations in neurology residency programs: unintended consequences. Neurology (2011) 1.69
Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A (1996) 1.68
Poverty and blindness in Pakistan: results from the Pakistan national blindness and visual impairment survey. BMJ (2007) 1.68
High-frequency transfection and cytopathology of the hepatitis B virus core antigen gene in human cells. Science (1983) 1.67
Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res (1985) 1.66
Cataract prevalence, cataract surgical coverage and barriers to uptake of cataract surgical services in Pakistan: the Pakistan National Blindness and Visual Impairment Survey. Br J Ophthalmol (2007) 1.66
Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res (1996) 1.65
Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res (1995) 1.64
Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation (1988) 1.64
Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res (1998) 1.64
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev (1996) 1.63
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol (1999) 1.62
Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest (2001) 1.61
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A (1997) 1.60
Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci U S A (1985) 1.60
Investigating the HLA component in rheumatoid arthritis: an additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet Epidemiol (1991) 1.60
Ecological and socio-economic assessment of Varthur wetland, Bengaluru (India). J Environ Sci Eng (2011) 1.59
Ultrasensitive enzymatic radioimmunoassay: application to detection of cholera toxin and rotavirus. Proc Natl Acad Sci U S A (1979) 1.58